Clinical trialsCompany release

Adagene doses first patient in Phase 1 trial of double-masked HER2×CD3 engager ADG138

Adagene Inc. (ADAG) · Thu 19 Nov 2026

The first-in-human study of ADG138, a SAFEbody-masked bispecific T-cell engager, enrols heavily pretreated patients with HER2-positive advanced solid tumours, including some who progressed after HER2-directed antibody-drug conjugates.

Adagene Inc. announced on 19 November 2026 that the first patient has been dosed in a Phase 1 trial of ADG138, its HER2×CD3 bispecific T-cell engager that uses the company's SAFEbody double-masking technology.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Adagene Inc. ↗

Article written by VigiEye from the official source (Adagene Inc.). Claims are the company's own. AI-assisted; check the source before acting.